IMMX
Immix Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMMX
Immix Biopharma, Inc.
A biopharmaceutical company that researches and develops drugs and therapies in the fields of oncology and inflammation
11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064
--
Immix Biopharma, Inc., was incorporated as a Delaware corporation on January 7, 2014. The Company is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (" CAR-T ") in light chain (AL) amyloidosis and autoimmune diseases. The Company's lead cell therapy drug candidate is CAR-T NXC-201, approved by the U.S. Food and Drug Administration (" FDA ") as an investigational new drug (" IND "), and is currently being evaluated in the Company's Phase 1 b/2 a NEXICART-1 (NCT04720313) clinical trial.
Company Financials
EPS
IMMX has released its 2024 Q2 earnings. EPS was reported at -0.15, versus the expected -0.21, beating expectations. The chart below visualizes how IMMX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
